DNA and Viral Vector Production Facility
Keele Science Park
Tel: +44 (0)1782 714181
About Cobra Biologics
Cobra Biologics, together with its parent company Cognate BioServices, is a leading international contract development and manufacturing organisation (CDMO) providing the highest quality development and manufacturing services for the cell and gene therapy fields, ranging from early stage development and pre-clinical services to clinical and commercial supply. Cobra and Cognate service an international customer base from its manufacturing and development facilities in the UK, Sweden, and the US.
Each of the Company's GMP approved facilities are tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for the clinical trial and the commercial markets.
As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.
Cobra, through Cognate is supported by leading shareholder EW Healthcare Partners, as well as Medivate Partners, Blackrock, and a Middle Eastern Sovereign Wealth Fund, who continue supporting the business and its expansion activities.
Microbiota, DNA Production and Fill Finish Facility
SE-864 31 Matfors
t: +46 (0)60 7858 600
Cobra Biologics Virtual Tour
49 articles about Cobra Biologics
8/20/2020Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
7/16/2020Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
Further milestone paves the way for production of novel gene therapy drug candidate designed to treat drug-resistant focal epilepsy
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
Cobra Biologics signs supply agreement with AstraZeneca for manufacture of COVID-19 vaccine candidate
Cobra Biologics (Cobra), part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, today announced it has signed a supply agreement with AstraZeneca UK Ltd. ("AstraZeneca") to provide GMP manufacture of th
Keele, UK, 31 March 2020: Cobra Biologics, an international CDMO for biologics and pharmaceuticals, announced it is working as part of a consortium led by the Jenner Institute, Oxford University to rapidly develop, scale-up and produce the potential adenoviral vaccine candidate, ChAdOx1 nCov-19, for fast-tracked clinical trials for COVID-19.
Cobra Biologics and the Karolinska Institutet, secured millions in emergency funding from Horizon 2020 to support research and development and an eventual Phase I clinical trial testing of a DNA vaccine against COVID-19.
Cognate BioServices, a leading contract development and manufacturing organization specialized in cell and cell-mediated gene therapy products announced that it has completed the acquisition of Cobra Biologics, a leading CDMO specialized in providing development and manufacturing services for plasmid DNA and viral vector.
11/7/2019Biotech and pharmaceutical companies from across the globe provide updates on their business and pipelines.
Transformative acquisition creates global cell and gene therapy manufacturing services platform for both clinical and commercial products
Collaboration supports progression of Epilepsy Gene Therapy toward clinical trials
6/27/2019Biotech and pharma companies from across the globe share pipeline and business updates.
Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) focused on viral vector drug substance production, and Symbiosis Pharmaceutical Services (Symbiosis), a contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable viral vector drug products, today announced the successful completion of their collaboration to develop synergistic and world leading capabilities.
1/18/2019Pharma and biotech companies make changes to their board and leadership teams to advance pipelines and strategies, at SQZ, AstraZeneca, Bioasis, and more.
Cobra Biologics (Cobra), an international CDMO for biologics and pharmaceuticals, today announced the appointment of Dr Darrell Sleep as Director of Innovation.
Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult Win £1.5M Innovate UK Grant to Investigate Continuous Manufacturing for Gene Therapies
Cobra Biologics has won a £1.5M shared grant from Innovate UK, the United Kingdom's innovation agency.
£100K grant will fund proof-of-concept studies to optimise bioprocessing of gene therapy vectors using hydrodynamic fluid flow fields
Cobra Biologics, GE Healthcare and Centre for Process Innovation Collaborate to Advance Gene Therapy
Innovate UK funded project supports development of scalable, cost effective production of regenerative medicines
The grant will position the partner companies as globally recognised centres of excellence in the field and firmly establish commercial viral vector manufacturing capabilities within the UK.
The extended capacity and capability will allow Cobra increased process development, analytics and GMP manufacturing.